Curetis and Quaphaco Enter into Unyvero Distribution Partnership for Vietnam
February 06 2020 - 12:59AM
- Exclusive distribution agreement for initial term of 3
years
- Quaphaco commits to minimum purchase totaling about EUR
1.9 million during initial term
Amsterdam, the Netherlands, San Diego,
CA, USA, and Holzgerlingen, Germany, February 6, 2020, 08:00 am
CET - Curetis N.V. (the "Company" and,
together with its subsidiaries, "Curetis"), a
developer of next-level molecular diagnostic solutions, today
announced that it has entered into a distribution agreement with
Quaphaco for Vietnam. Quaphaco, headquartered in Ho Chi Minh City,
is a leading medical equipment supplier in Vietnam that is already
working with numerous renowned global IVD manufacturers.
Under the agreement, Quaphaco has the exclusive
right to commercialize Curetis’ Unyvero A50 instrument system and
application cartridges for the diagnosis of severe infections in
hospitalized patients in Vietnam. The agreement has a term of
initially three years and can be extended by two-year increments.
In return, Quaphaco has committed to significant minimum purchases
of Unyvero instruments and application cartridges over the initial
3-year term of the agreement amounting to a total of about EUR 1.9
million revenue to Curetis. Quaphaco is responsible for product
registration that is expected by Q2-2020 and has committed to
significantly invest into the market introduction of the Unyvero
product line in Vietnam.
With 88-97% of drug stores in Vietnam dispensing
antibiotics without a prescription despite the fact that it is
prohibited by Vietnamese law and despite antibiotics accounting for
more than 50% of drugs used in human medicine, antimicrobial
resistance is among the most severe threats to human health in
Vietnam (Ref 1). Responding to this threat, Vietnam in 2013 became
the first country in the World Health Organization’s (WHO) Western
Pacific Region to approve a national action plan to combat
antimicrobial resistance (Ref 2).
“With at least one in ten patients suffering
from healthcare-associated infections in Vietnam, we believe that a
rapid and comprehensive detection of the pathogens and their
antibiotic resistance markers with Unyvero will help to improve
outcomes for patients with severe infections while supporting the
antibiotic stewardship efforts that are high on the agenda of our
public health institutions,” said Dr. Mai Van Phong, CEO of
Quaphaco.
“We are very pleased to work with Quaphaco as a
highly committed partner in making Unyvero available in Vietnam,”
commented Oliver Schacht, PhD, CEO of Curetis. “This partnership
strengthens our commercial presence in the ASEAN region and
complements our commercial efforts with our partner Acumen Research
Laboratories in Singapore, Indonesia, Thailand, and Malaysia.”
###
References
-
https://www.who.int/vietnam/health-topics/antimicrobial-resistance
-
https://www.cdc.gov/drugresistance/solutions-initiative/stories/tracking-resistance-in-vietnam.html
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly-owned subsidiary Ares Genetics
GmbH offers next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
what the Company believes to be the most comprehensive database
worldwide on the genetics of antimicrobial resistances, ARESdb,
with advanced bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Curetis International Media &
Investor InquiriesakampionDr. Ludger Wess / Ines-Regina
Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20200206_Curetis_PR_Distribution_Vietnam_final_approved
Direxion Daily Healthcar... (AMEX:CURE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Direxion Daily Healthcar... (AMEX:CURE)
Historical Stock Chart
From Oct 2023 to Oct 2024
